实验室医学中的患者风险管理:一项评估错误报告结果相关伤害严重性的国际调查
该研究通过Bio-Rad平台对43个国家267名医学检验专业人员开展国际调查,要求其对20项检验项目因错误报告结果可能导致的患者伤害进行五级分类评估。结果显示19/20项参数至少被归类为严重伤害,无项目被归为可忽略伤害。这是首个探讨实验室界如何认识错误报告结果所致患者伤害的国际研究,为以患者风险为中心的实验室风险管理政策提供依据。
要点
- 19/20项检验项目错误报告至少导致严重伤害,无项目为可忽略伤害。
- 267名来自43国的检验专业人员参与五级伤害严重性分类评估。
- 结果为实验室风险管理政策提供以患者风险为中心的文档支持。
核心结论
- 该研究首次国际性调查实验室界对错误报告结果所致患者伤害的认知,几乎所有参数(19/20)至少被归类为严重伤害,无参数被归为可忽略伤害。
研究设计与样本
- 由Bio-Rad面向客户及公众发布网络问卷调查,要求参与者对20项检验项目按五级伤害类别(可忽略、轻微、严重、危急、灾难性)评定错误报告结果可能导致的伤害,并收集人口学特征;共分析来自43个国家的267份问卷。
主要发现
- 267名来自43个国家的受访者问卷被分析,为每个检验项目分配了特定伤害类别。
- 几乎所有参数(19/20)被归类为至少严重伤害类别,无参数与可忽略类别相关联。
关键数值与推荐
- 伤害分类采用五个预定义类别:可忽略、轻微、严重、危急、灾难性。
- 20项检验项目中19项至少归为严重伤害,0项归为可忽略伤害。
临床怎么用
- 研究结果可用于记录实验室风险管理政策,该政策现在必须以患者风险为中心。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Patient risk management is an essential subject for clinical laboratory which is now central in main international laboratory quality standards (e.g., ISO 15989:2022; ISO 22367:2020 and CLSI EP232nd). Risk analysis is a necessary part of risk management which requires categorizing the severity of patient harm from a laboratory failure. However, this subjective task is not currently the subject of any recommendation and little literature about this topic. To remedy that, we conducted an international survey of medical biology professionals, asking them to rate a panel of 20 analytes the harm potentially induced by an erroneous reported result. METHODS: The survey was published by Bio-Rad® to their customers base and the public with a dedicated webpage. The survey proposes to assign for the submitted analytes the amount of harm among five pre-defined categories of harm: negligible, minor, serious, critical, and catastrophic. Participants were also asked to specify their demographic characteristics. RESULTS: The questionnaires of 267 respondents coming from 43 countries were analyzed to allocate for each analyte a specific harm category. We highlight that almost all parameters (19/20) were categorized with at least a serious harm category and that none were associated with the negligible category. CONCLUSIONS: This study constitutes the first international attempt to investigate how the laboratory community thinks about patient harm from an erroneous reported result. These results provide support to document the laboratory risk management policy which must now be centered on patient risk.
引用
- Peltier L, Van Aelst S, Peeters B, et al. Patient risk management in laboratory medicine: an international survey to assess the severity of harm associated with erroneous reported results. Clin Chem Lab Med. 2025. PMID: 40023847. doi:10.1515/cclm-2024-1477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。